反応式
C([O:8][C@@H:9]1[C@@H:21]([CH2:22][O:23]CC2C=CC=CC=2)[S:20][CH:11](SCC2C=CC=CC=2)[CH2:10]1)C1C=CC=CC=1.BrBr.[CH2:33]([C:35]1[C:36](=[O:42])[NH:37][C:38](=[O:41])[NH:39][CH:40]=1)[CH3:34]>C(Cl)(Cl)(Cl)Cl.C[Si](C)(C)N[Si](C)(C)C.Cl[Si](C)(C)C.[Hg](Br)Br>[CH2:33]([C:35]1[C:36](=[O:42])[NH:37][C:38](=[O:41])[N:39]([CH:40]=1)[C@@H:11]1[S:20][C@H:21]([CH2:22][OH:23])[C@@H:9]([OH:8])[CH2:10]1)[CH3:34]参加物
反応物 3
生成物 1
試薬・触媒・溶媒 4
実験手順
Benzyl 3,5-di-O-benzyl-2-deoxy-1,4-dithio-D-erythro-pentofuranoside (5.6 mmol) was dissolved in CCl4 (30 ml) and bromine (6.2 mmol) in CCl4 (30 ml) was added. After stirring for 5 min. at ambient temperature the solvent was evaporated and the residue re-evaporated from CCl4 (10 ml) to remove excess bromine. To a solution of this crude 1-bromothiosugar in CCl4 (15 ml) was added bis-O-trimethylsilyl-5-ethyl uracil (16.6 mmol) [prepared by refluxing 5-ethyluracil (16.6 mmol) in a mixture of hexamethyldisilazane (50 ml) and chlorotrimethylsilane (5 ml) for 2 h., and evaporation of the solvents], HgBr2 (1.99 g; 5.5 mmol) and CdCO3 (2.36 g; 16.6 mmol). The solvent was evaporated and the residue heated at 100° C. for 1 h. The residue was worked up as for the thymidine analogue and the product purified by column chromatography. The benzyl ether protecting groups were removed by treatment with BCl3 as described for the 5-iodo analogue.
後処理
- customwas evaporated
- customthe residue re-evaporated from CCl4 (10 ml)
- customto remove excess bromine
- customprepared
- customThe solvent was evaporated
- temperaturethe residue heated at 100° C. for 1 h
- customthe product purified by column chromatography
- customThe benzyl ether protecting groups were removed by treatment with BCl3
出典と根拠
- ORDレコード
- ord-01c2525e0c0d4ee3ae36a4d8f7b3f993
- 出典データセット
- uspto-grants-1996_05
- 特許番号
- US05521163
関連ノート
読み込み中…